ACOR : Analysis & Opinions

  1. Acorda's Ampyra in Phase III for Post-Stroke Walking Deficit ...

    December 16, 2014
    Acorda (ACOR) has commenced a phase III study on Ampyra for the treatment of post-stroke walking deficits.
Trading Center